Home > Pressrelease > Rat model Market size to exceed $2.3bn by 2028

Rat model Market size to exceed $2.3bn by 2028

  • Published Date: April 26, 2022

Rat Model Market size is set to surpass USD 2.3 billion by 2028, according to a new research report by Global Market Insights Inc.

The emergence of clustered regularly interspaced short palindromic repeat or CRISPR mechanism represents a notable milestone in genome editing technology that is employed in a broad range of experiments. Amongst these, the third-generation gene editing mechanism referred to as Streptococcus pyogenes Cas9 (SpCas9) possesses the immense potential to efficiently promote mutations at specific target positions in the genome. Genetically modified rats that have similarities with human anatomy and reproduce diseases are very essential for the study of numerous pathological conditions.

Clinical advantages offered by the outbred rat models will drive the rat model market revenue

Outbred segment exceeded USD 346 million in 2021. This is owing to the surging adoption of transgenic outbred rat model-based research in infectious disorders studies, quality outcomes offered in investigational research, among others. Outbred rat testing is considered as highly suitable and preferred to evaluate or model the human population. Pertaining to their phylogenetic similarities and physiological relatedness to humans, low maintenance, ease of breeding them in the laboratory, and the easy access to numerous outbred strains, these strains have been predominantly used as models of human biology and disease. Thus, the above-mentioned factors will fuel the market demand.

Favourable government initiatives and the adoption of microinjection technology will boost the business expansion

Rat model market from microinjection segment is predicted to register 7.4% CAGR from 2022 to 2028. Microinjection is an essential technique that is majorly used in the development of genetically modified rat models. Different microinjection mechanisms are used to generate these models based on construction and configuration requirements.

For instance, knockout as well as knock in rat strains, transgenic rat strains, and targeted-mutant rats are produced using this technology. The adoption of these technologies is growing worldwide due to their application in a broad range of species, effectiveness & reliability in mammals, etc. The transgenic rats produced through microinjection are playing a significant role in research concerned with several therapeutic areas comprising cancer, diabetes, and cardiovascular research among others. Thus, the rise in the use of microinjection technology will foster the overall industry landscape.

Browse key industry insights spread across 650 pages with 750 market data tables & 20 figures & charts from the report, Rat Model Market Analysis By Rat Type (Inbred, Outbred, Knockout, Hybrid), By Technology (CRISPR, Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer), By Application (Research & Development, {Infectious Disease, Immunological Disease, Cancer, Cardiovascular Diseases, Diabetes, Genetic Diseases, Neurological Diseases}, Production And Quality Control, Academics), By Use (Human, Veterinary), By End-use (Companies {Pharmaceutical, Biotechnology, Cosmetics}, Organizations {Government, Non-Government}, Academic And Research Institutes, Contract Research Organizations), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028in detail along with the table of contents:

Several advantages delivered by the rat model in production and quality control will spur the market progression

Rat model market from production and quality control segment surpassed USD 218 million in 2021. Production and quality control applications include rat testing that is an essential step in enhancing the efficacy of production & quality control, understanding pharmacology relationships in clinical trials, etc. Rat model-based research assists in understanding medical product assessment during the production phase. A standardized rat model has the potential to address regulatory safety concerns and offer insights related to further de-risking during product validation. The appropriate use of genetically engineered rat strains assists production and quality control researchers in catering to several concerns raised by the inception of a novel chemical reagent in the market.

Growing adoption of rat models in animal diseases studies will augment the industry expansion

Veterinary segment is anticipated to expand at 7.3% CAGR during the analysis period. The surging prevalence of zoonotic and foodborne diseases & increasing disease burden of animal diseases will positively influence the rat model market statistics. For instance, the Animal Health and Disease Research Capacity Program was implemented by the U.S. government with the intention of funding to encourage animal health research in veterinary schools or at experiment stations. Thus, the increasing prevalence of zoonotic diseases and government initiatives will propel the market outlook. 

Increasing adoption of the rat model by contract research organizations (CROs)will boost the market statistics

Rat model market from CRO segment was valued at over USD 103 million in 2021. This is attributed to the increasing number of clinical trial studies. The growing emphasis of pharma companies on R&D activities for the development of novel products is set to render a positive impact on the CRO segment. New drug approval and technological advancements also provide impetus to the adoption of rat testing in contract research organizations. Pharmaceutical firms are increasingly adopting R&D outsourcing strategies to maximize their operational performance. The growing outsourcing of R&D activities applications by pharmaceutical & biotechnology companies has significantly augmented the segment revenue.

Growing rat model-based research adoption in the Europe will propel the regional business growth

France rat model market exceeded USD 15 million in 2021. The rising rat model adoption for biomedical research, the surging expenditure & investments in developing personalized medicine, and extensive applications of rat models in the healthcare domain will accelerate the regional industry trend. Further, rat testing is an integral part of research institutes as they are extensively used for leading experiments, education purposes, etc. The rat model-based research also plays a significant role in the study of chronic ailments and is highly applied by biotechnology companies in the country to test the efficacy of drugs. Thus, the above-mentioned factors are projected to drive the regional industry landscape.  

Key players are adopting several business strategies to capture significant market share

Some of the major players operational in the rat model industry are Charles River, Envigo, genOway, Biomere, Janvier Labs, and Taconic Biosciences, Inc. among others. Increasing focus of the market players on manufacturing and developing innovative products for effective treatment of diseases will provide significant growth opportunities. These players are proposing strategic acquisitions, mergers, collaborations, and partnerships to launch new research model and strengthen their industrial position.

Authors: Sumant Ugalmugle, Rupali Swain

Explore More on Related Topics: